Zobrazeno 1 - 10
of 29
pro vyhledávání: '"James M. Roach"'
Publikováno v:
Drugs in R&D. 23:43-53
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b920b56f3fd5ee05d5a589deb2297fbb
https://doi.org/10.1007/s40268-022-00410-6
https://doi.org/10.1007/s40268-022-00410-6
Autor:
David P. Ryan, Eileen M. O'Reilly, Kenneth H. Yu, James M. Roach, Donald A. Richards, Spencer H. Shao, Julie Wolf, Tanios Bekaii-Saab, Diletta Barone, Keith T. Flaherty, Devalingam Mahalingam, Molly Rosano, Silva Krause
Publikováno v:
Eur J Cancer
Background Necuparanib, a rationally engineered low-molecular-weight heparin, combined with gemcitabine/nab-paclitaxel showed an encouraging safety and oncologic signal in a phase Ib trial. This randomised multicentre phase II trial evaluates the add
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d46d4deab624d9e62e9c043b527eb809
https://doi.org/10.1016/j.ejca.2020.03.005
https://doi.org/10.1016/j.ejca.2020.03.005
Autor:
James M. Roach, Janet M. Price, Robert Rubens, Thomas J. Schnitzer, David A. Amato, Thomas Roth
Publikováno v:
The Primary Care Companion to The Journal of Clinical Psychiatry. 11:292-301
To evaluate the efficacy and safety of eszopiclone 3 mg, a nonbenzodiazepine medication/hypnotic indicated for the treatment of insomnia with comorbid rheumatoid arthritis (RA).This multicenter, double-blind, placebo-controlled pilot study was conduc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::620ac856e68aba51dbcc2fad5ef1ee4c
https://doi.org/10.4088/pcc.08m00749bro
https://doi.org/10.4088/pcc.08m00749bro
Autor:
L. L. Jackson, Ensign James M. Roach
Publikováno v:
Journal of the American Society for Naval Engineers. 72:211-220
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::648126eb7e526c3d25a5b684c5b7c0ee
https://doi.org/10.1111/j.1559-3584.1960.tb01850.x
https://doi.org/10.1111/j.1559-3584.1960.tb01850.x
Autor:
James F. Donohue, L Noe, Ronald L. Ciubotaru, Kendyl Schaefer, Nicola A. Hanania, James M. Roach, William T. Andrews, David J. Pasta, Raymond Claus
Publikováno v:
Clinical Therapeutics. 30:989-1002
The National Heart, Lung, and Blood Institute guideline recommends that dosing racemic albuterol be administered every 1 to 4 hours for treating patients with asthma or chronic obstructive pulmonary disease (COPD) in the hospital. Previously publishe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::08566dd2c53dd41f6535c785410984ed
https://doi.org/10.1016/j.clinthera.2008.06.010
https://doi.org/10.1016/j.clinthera.2008.06.010
Publikováno v:
Sleep Medicine. 8:464-470
Objective To evaluate the effects of eszopiclone on measures of respiration and sleep using polysomnography in patients with mild to moderate obstructive sleep apnea syndrome (OSAS). Methods This double-blind, randomized crossover study included pati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4e103409bb2ba8aac4056bd999890b2d
https://doi.org/10.1016/j.sleep.2006.10.007
https://doi.org/10.1016/j.sleep.2006.10.007
Autor:
Rudolf A. Baumgartner, James M. Roach, Leon S Greos, Merdad V. Parsey, David P. Skoner, Kenneth Kim
Publikováno v:
Pediatric Pulmonology. 40:477-486
The purpose of this study was to evaluate the safety and efficacy of single-isomer (R)-albuterol (levalbuterol, LEV) in children aged 2-5 years. Children aged 2-5 years (n = 211) participated in this multicenter, randomized, double-blind study of 21
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::40db7885b36b2da69d3a69c7d7872c61
https://doi.org/10.1002/ppul.20288
https://doi.org/10.1002/ppul.20288
Autor:
Louis Vaickus, Rachel L DiSantostefano, James M. Roach, Richard M. Nowak, Charles L. Emerman, Kendyl Schaefer
Publikováno v:
The American Journal of Emergency Medicine. 22:29-36
This was a prospective, open-label, nonrandomized pilot study to evaluate efficacy and tolerability of levalbuterol (LEV) in acute asthma. Asthmatics (forced expiratory volume in 1 second [FEV1], 20-55% predicted) were sequentially enrolled into coho
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::13e1dbc876dca9232fa34b8bf05dda93
https://doi.org/10.1016/j.ajem.2003.11.001
https://doi.org/10.1016/j.ajem.2003.11.001
Autor:
Catherine Tjan, Keith T. Flaherty, James M. Roach, Silva Krause, Eileen M. O'Reilly, Paul J. E. Miller, Darrell Nix, Kenneth H. Yu, Molly Rosano, William Avery, David P. Ryan, Julie Wolf
Publikováno v:
The Oncologist
Lessons LearnedDespite the compelling preclinical rationale of evaluating the genetically engineered heparin derivative, necuparanib, combined with standard therapy in metastatic pancreas adenocarcinoma, the results were ultimately disappointing. Saf
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::edf0a6ecdc7404a790e99323052f6eae
http://europepmc.org/articles/PMC5728039
http://europepmc.org/articles/PMC5728039
Autor:
James M. Roach, Paul J. E. Miller, Eileen M. O'Reilly, Molly Rosano, David P. Ryan, Silva Krause, Louis Vaickus, William Avery, Tanios Bekaii-Saab, Keith T. Flaherty, Devalingam Mahalingam, Donald A. Richards, Spencer H. Shao, Julie Wolf
Publikováno v:
Journal of Clinical Oncology. 35:370-370
370 Background: The Phase 1 portion of a Phase 1/2 trial of Necuparanib (“Necu”) combined with nab-paclitaxel (nabP) + gemcitabine (gem) in patients with metastatic pancreatic cancer (ClinicalTrials.gov Identifier NCT01621243) showed acceptable s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::42b6717f105bd2cc6098f7bef920f01b
https://doi.org/10.1200/jco.2017.35.4_suppl.370
https://doi.org/10.1200/jco.2017.35.4_suppl.370